EAN 2025: Efgartigimod Approved in EU for CIDP

At EAN 2025, Professor Giuseppe Lauria presented results from the ADHERE trial, showing that efgartigimod is effective in treating CIDP with a response rate of around 60%. Recently, efgartigimod was approved in the EU for the treatment of CIDP. Efgartigimod is administered subcutaneously, which reduces the need for hospital-based treatment and minimizes side effects.